Phone
Address Talkabouturology, Nizhny Novgorod, Russia
Skype ukitcom
Email Talkabouturology@list.ru
                                    Talk about urology
Back to the list

Among treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC), darolutamide may provide the best overall survival (OS) benefit, whereas abiraterone may be the most cost-effective.

https://www.renalandurologynews.com/home/news/urology/prostate-cancer/nmcrpc-darolutamide-enzalutamide-apalutamide-abiraterone-efficacy-comparison/?utm_source=social&utm_medium=facebook&utm_content=ccedf268-ad4c-46b0-b928-1b521f9cba18&utm_campaign=run_daily_posts